RGDXQ / Response Genetics, Inc - Depositi SEC, Relazione annuale, dichiarazione di delega

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 5 Passive Investment

SC 13G/A 1 response13gam5dec2015.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this S

RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS (UK) LLP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.

RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) November 18, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of inco

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of (IRS

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State or other jurisdiction of (IRS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Bankruptcy or Receivership

8-K 1 v4176958k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-33509 Delaware 11-3525548 (State o

Response Genetics, Inc. Terms and Conditions of Proposed Senior Secured, Super-Priority Debtor-in-Possession Credit Facility

Exhibit 10.2 Response Genetics, Inc. Terms and Conditions of Proposed Senior Secured, Super-Priority Debtor-in-Possession Credit Facility The terms outlined below in this Terms and Conditions (this ?DIP Term Sheet?) are the terms and conditions for a senior secured, super-priority debtor-in-possession credit facility (hereinafter referred to as the ?DIP Facility?) to be made available to the Debto

ASSET PURCHASE AGREEMENT BY AND BETWEEN RESPONSE GENETICS, INC., A DELAWARE corporation AND CANCER GENETICS, INC., a DELAWARE CORPORATION Dated as of AUGUST 9, 2015 Table of Contents

Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN RESPONSE GENETICS, INC., A DELAWARE corporation AND CANCER GENETICS, INC., a DELAWARE CORPORATION Dated as of AUGUST 9, 2015 Table of Contents Page 1. Purchase and Sale 1 1.1 Assets to Be Transferred 1 1.2 Excluded Assets 3 1.3 Liabilities 5 1.4 Purchase Price; Deposit; and Allocation of Purchase Price 7 1.5 Closing 8 1.6 Closing Deliveries by S

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

THIRD AMENDMENT TO CREDIT AGREEMENT

Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of June 25, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (?Borrower?), each of the undersigned financial institutions party hereto as lenders (individually each a ?Lender? and collectively ?Lenders?), and SWK FUNDING LLC, a Delaware limited li

RGDX FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33509 RESPONSE GEN

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

Response Genetics, Inc. Announces First Quarter 2015 Financial Results

EX-99.1 2 v410705ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces First Quarter 2015 Financial Results LOS ANGELES, May 14, 2015 — Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development

RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) April 3, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

SECOND AMENDMENT TO CREDIT AGREEMENT

Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of April 3, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (?Borrower?), each of the undersigned financial institutions party hereto as lenders (individually each a ?Lender? and collectively ?Lenders?), and SWK FUNDING LLC, a Delaware limited

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 v4061778-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of

Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results Response DX Revenue increased 16% and 22% over Fourth Quarter and Full Year 2013 Respectively

EX-99.1 2 v406177ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results Response DX Revenue increased 16% and 22% over Fourth Quarter and Full Year 2013 Respectiv

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

FIRST AMENDMENT TO CREDIT AGREEMENT

Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of February 3, 2015, is entered into by and among Response Genetics, Inc., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in it

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2015 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Empl

CREDIT AGREEMENT Response genetics, inc., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, the financial institutions party hereto from time to time as Lenders Dated as of July 30, 2014

EX-10.1 2 v399569ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT among Response genetics, inc., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of July 30, 2014 [ResGen] Credit Agreement Table of Contents Page Section 1 Definitions; Interpretation 1 1.1 Definiti

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

8-K 1 v3954038-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

Response Genetics, Inc. Announces Third Quarter 2014 Financial Results ---ResponseDX® quarterly revenues increase 54% over prior year ---

EX-99.1 2 v394176ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Third Quarter 2014 Financial Results -ResponseDX® quarterly revenues increase 54% over prior year - LOS ANGELES, November 13, 2014 — Response

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti

AMENDMENT NO. 1 EMPLOYMENT AGREEMENT

EX-10.1 2 v390433ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 (“Amendment”) to the Agreement (defined below) is entered into as of September 25, 2014 between Thomas A. Bologna (“Executive”) and Response Genetics, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company and Executive are parties to that certain employment agreement date

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 v3867788k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission Fil

Response Genetics, Inc. Announces Second Quarter 2014 Financial Results ---ResponseDX® Revenue sets record for quarterly DX sales as testing volume again increases over prior quarter ---

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Second Quarter 2014 Financial Results -ResponseDX® Revenue sets record for quarterly DX sales as testing volume again increases over prior quarter - LOS ANGELES, August 14, 2014 — Re

RGDX / S-3/A - - S-3/A

As filed with the Securities and Exchange Commission on August 12, 2014 Registration No.

CREDIT AGREEMENT Response genetics, inc., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, the financial institutions party hereto from time to time as Lenders Dated as of July 30, 2014 Table of Contents

EX-10.1 2 v385757ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION VERSION CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS AGREEMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CREDIT AGREEMENT among Response genetics, inc., as Borrower, SWK FUNDING LLC, as Ag

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission Fil

RGDX / S-3 - - FORM S-3

As filed with the Securities and Exchange Commission on July 21, 2014 Registration No.

EX-3.1

EX-3.1 2 v383790ex3-1.htm EXHIBIT 3.1

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

8-K 1 v3837908-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

- FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of N

Response Genetics, Inc. Announces First Quarter 2014 Financial Results --- ResponseDX® Revenue and testing volumes increase relative to Q4 2013 ---

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

RGDXQ / Response Genetics, Inc. / Northern Right Capital Management, L.P. - SCHEDULE 13D AMENDEMENT NO. 7 Activist Investment

SC 13D/A 1 d706538dsc13da.htm SCHEDULE 13D AMENDEMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) * RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker Attn: Matth

RGDX FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-33509 RESPONSE GENETICS, INC. (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2014 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission Fi

Response Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 3 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

RGDXQ / Response Genetics, Inc. / Northern Right Capital Management, L.P. - SCHEDULE 13D AMENDMENT NO. 6 Activist Investment

Schedule 13D Amendment No. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) * RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker Attn: Matthew A. Drapkin 500 Crescent Cour

RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.

RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) January 2, 2014 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate the rul

4,464,443 Shares RESPONSE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT

4,464,443 Shares RESPONSE GENETICS, INC. Common Stock UNDERWRITING AGREEMENT December 13, 2013 NATIONAL SECURITIES CORPORATION 410 Park Avenue, 14th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Response Genetics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell to National Securities Corpora

Response Genetics, Inc. Announces Pricing of Underwritten Public Offering

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Response Genetics, Inc. National Securities Corporation TABLE OF CONTENTS PROSPECTUS SUPPLEMENT SUMMARY THE OFFERING CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS RISK FACTORS Risks Related to This Offering Risks Related to Our Business,

Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 4,464,443 Shares Response Genetics, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 4,464,443 shares of our common stock at a public offering price of $1.20 per share. Our common stock is quoted on The NASDAQ Capital Market

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

RESPONSE GENETICS, INC. FREE WRITING PROSPECTUS

ISSUER FREE WRITING PROSPECTUS Dated December 12, 2013 Filed Pursuant to Rule 433 Registration No.

Response Genetics, Inc. Announces Proposed Underwritten Public Offering

EX-99.1 2 v362818ex99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces Proposed Underwritten Public Offering LOS ANGELES, December 12, 2013 — Response Genetics, Inc. (Nasdaq: RGDX) (the “Company”), a company focused on the de

Subject to Completion Preliminary Prospectus Supplement, dated December 12, 2013 Response Genetics, Inc. National Securities Corporation TABLE OF CONTENTS PROSPECTUS SUPPLEMENT SUMMARY THE OFFERING CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATE

The information in this preliminary prospectus supplement is not complete and may be changed.

Submission of Matters to a Vote of Security Holders - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

Response Genetics, Inc. Announces Third Quarter 2013 Financial Results

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

- FORM DEFA 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

-

Response Genetics, Inc. 1640 Marengo Street, 6th Floor Los Angeles, CA 90033 September 30, 2013 VIA EDGAR AND FEDEX Mr. Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Response Genetics, Inc. Form 10-K Filed March 27, 2013 File No. 001-33509 Dear Mr. Riedler: Reference is made to th

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti

932,805 Shares Response Genetics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 932,805 Shares Response Genetics, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering an aggregate of up to 932,805 shares of our common stock directly to investors at a price per share of $2.05. Our common stock is quoted on T

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdicti

PLACEMENT AGENCY AGREEMENT

Exhibit 10.1 PLACEMENT AGENCY AGREEMENT September 19, 2013 Ladenburg Thalmann & Co. Inc. 520 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Response Genetics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell an aggregate of $1,912,250.25 of registered securities (the “Securities”) of the Compan

Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering --Proceeds to be used for launch of recently acquired FDA-Cleared and Medicare-reimbursed test for difficult to diagnose tumors--

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering -Proceeds to be used for launch of recently acquired FDA-Cleared and Medicare-reimbursed test for difficult to diagnose tumors- LOS ANGELES, S

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

8-K 1 v3537108-k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commiss

ASSET PURCHASE AGREEMENT

EXHIBIT 10.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is hereby entered into on August 23, 2013 (the “Effective Date”), by and between Pathwork (assignment for the benefit of creditors), LLC(“Seller”), a California limited liability company, in its sole and limited capacity as assignee for the benefit of creditors of Pathwork Diagnostics, Inc., wit

Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors -- Acquisition expected to complement and add material sales to Company’s Dx business --

EX-99.1 3 v353710ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Chairman & Chief Executive Officer 646-378-2973 323-224-3900 Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors - Acquisition expected t

500,000 Shares Response Genetics, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-171266 PROSPECTUS SUPPLEMENT To Prospectus dated January 6, 2011 500,000 Shares Response Genetics, Inc. Common Stock Response Genetics, Inc. is offering an aggregate of 500,000 shares of its common stock all of which will be issued directly to certain designees of Pathwork (assignment for the benefit of creditors), LLC (“Seller”). The shares of

Response Genetics, Inc. Announces Second Quarter 2013 Financial Results --- Second Quarter 2013 Revenue increases over 38% to $5.3 million and loss decreases over two-fold to $1.3 million relative to Q2 2012 ---

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o

RGDXQ / Response Genetics, Inc. / Northern Right Capital Management, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) Becker Drapkin Management, L.P. Attn: Steven R. Becker 500 Crescent Court, Suite 230 Dallas, Texas 75201 (214) 756-6016 (Name, Address

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction of

EMPLOYMENT AGREEMENT

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of June 12, 2013 (the “Effective Date”) between Response Genetics, Inc., a Delaware Corporation (the “Company”) and Kevin R. Harris (“Executive”). WHEREAS, Executive has served as Interim Chief Financial Officer of the Company since August 20, 2012; and WHEREAS, Executive and the Company desire to enter into this

Response Genetics, Inc. Announces First Quarter 2013 Financial Results --- Q1 Revenue increases over 40% to $5.6 million relative to Q1 2012 and Gross Margin increases to 55% --- --- First Quarter Losses decrease to $0.8 million relative to Q1 2012 l

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other jurisdiction of incorporation) (Commission File

Response Genetics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results --- Q4 Revenue increases 11% to $5.5 million relative to Q4 2011and Gross Margin increases to 54% --- --- Fourth Quarter Losses decrease to $0.5 million relative to

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction o

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.

Response Genetics, Inc. Announces Third Quarter Financial Results --- Revenue increases to $5.4 million --- --- Third consecutive quarter of increased gross margin coupled with significant decrease in net loss ---

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

8,000,000 Shares RESPONSE GENETICS, INC. Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-184614 PROSPECTUS 8,000,000 Shares RESPONSE GENETICS, INC. Common Stock This prospectus covers 8,000,000 shares of common stock of Response Genetics, Inc. (“RGI”) that may be sold or otherwise disposed of from time to time by the selling stockholders named herein, or their transferees. We will not receive any of the proceeds from such sales. Th

- S-3

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 26, 2012 REGISTRATION NO.

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-33509 11-3525548 (State or other (Commission File (IRS Employer jurisdiction

Response Genetics Regains Compliance with NASDAQ Listing Standards

FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A.

RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC - AMENDMENT NO.1 TO SCHEDULE 13G Passive Investment

Amendment No.1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) September 13, 2012 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate

RGDXQ / Response Genetics, Inc. / GLAXOSMITHKLINE PLC Passive Investment

SC 13G 1 glaxorg-13g0921.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Response Genetics, Inc. (Name of Issuer) Common Stock, Par Value $0.01

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisd

PURCHASE AGREEMENT

Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of the 13th day of September, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and the investors set forth in Exhibit A hereto (each an “Investor” and collectively, the “Investors”). Recitals A. The Company and each Investor are executing and delivering this Ag

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 13th day of September, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and each investor set forth on the signature pages hereto and any Affiliate or permitted transferee of any such investor who is a subsequent ho

Response Genetics Raises $8.8 Million in Financing Company to Present at UBS Global Life Sciences in NYC on September 20, 2012

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Company Contact: Peter Rahmer Thomas A. Bologna Trout Group Response Genetics, Inc. 646-378-2973 323-276-6060 Response Genetics Raises $8.8 Million in Financing Company to Present at UBS Global Life Sciences in NYC on September 20, 2012 LOS ANGELES, September 13, 2012 – Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdict

Response Genetics

EXHIBIT 10.1 Response Genetics 1640 Marengo St., 6th Floor Los Angeles, CA 90033 Telephone: (323) 224-3900 Facsimile: (323) 224-3094 August 15, 2012 Via Email Kevin Harris [Address Redacted] RE: Temporary Employment with Response Genetics, Inc. Dear Kevin: It is with pleasure that we offer you a temporary position as Interim CFO for Response Genetics, Inc. (“RGI”). You have the talent and training

Response Genetics, Inc. Announces Second Quarter Financial Results --- Second consecutive quarter of decreased net loss and increased gross margin ---

EX-99.1 2 v321317ex99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Peter Rahmer Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces Second Quarter Financial Results - Second consecutive quarter of decreased net loss and increased gross margin - LOS ANGELES, August 14, 2012 — Response Genetics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdict

Submission of Matters to a Vote of Security Holders - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

SECOND AMENDED AND RESTATED MASTER SERVICES AGREEMENT

Exhibit 10.1 Portions of this Exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by [***]. Confidential SECOND AMENDED AND RESTATED MASTER SERVICES AGREEMENT PREAMBLE Thi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdictio

- SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdiction

5,257,267 Shares RESPONSE GENETICS, INC. Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-181045 PROSPECTUS 5,257,267 Shares RESPONSE GENETICS, INC. Common Stock This prospectus covers up to 5,257,267 shares of common stock of Response Genetics, Inc. (“RGI”) that may be sold or otherwise disposed of from time to time by the selling stockholders named herein, or their transferees. We will not receive any of the proceeds from such sal

Response Genetics, Inc. Announces First Quarter Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces First Quarter Financial Results LOS ANGELES, May 10, 2012 — Response Genetics Inc. (Nasdaq: RGDX), (the “Company”), a company focused on the development and sale of molecular diagnostic tests

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdiction

- S-3

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 30, 2012 REGISTRATION NO.

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - AMENDMENT NO. 1 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) April 16, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

RGDXQ / Response Genetics, Inc. / 12 West Capital Management LP - RESPONSE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RESPONSE GENETICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 76123U105 (CUSIP Number) April 16, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

- NT 10-K

SEC FILE NUMBER 001-33509 CUSIP NUMBER 76123U105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Response Genetics, Inc. Announces Year-End and Fourth Quarter Financial Results 2011 ResponseDX® Revenues increase over 2010

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck Trout Group Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics, Inc. Announces Year-End and Fourth Quarter Financial Results 2011 ResponseDX® Revenues increase over 2010 LOS ANGELES, March 27, 2012 — Response Genetics Inc. (Nasdaq: RGDX), a company focused on the develo

Financial Statements and Exhibits, Results of Operations and Financial Condition -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdicti

RGDXQ / Response Genetics, Inc. / Serruya Samuel - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Response Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U 105 (CUSIP Number) December 31, 2011 (Dat

Response Genetics Regains NASDAQ Compliance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Contact: Media Relations Contact: Michaela Parnell Barry Sudbeck The Trout Group LLC Fleishman-Hillard 646-378-2956 415-318-4261 Response Genetics Regains NASDAQ Compliance LOS ANGELES, February 21, 2012 – Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced to

Financial Statements and Exhibits, Other Events -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdi

RGDXQ / Response Genetics, Inc. / BRIDGER MANAGEMENT, LLC - SCHEDULE 13G Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RESPONSE GENETICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 76123U105 (CUSIP Number) February 2, 2012 (Date of Event which requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu

RGDXQ / Response Genetics, Inc. / LANSDOWNE PARTNERS LIMITED PARTNERSHIP Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response………11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2012 RESPONSE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-1124608 11-3525548 (State or other (Commission File (IRS Employer jurisdic

FORM OF REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 2nd day of February, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and the “Investor” named in that certain Purchase Agreement, by and among the Company and the Investor, dated as of the date hereof (the “Purchase Agreemen

FORM OF PURCHASE AGREEMENT

Exhibit 10.1 FORM OF PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of the 2nd day of February, 2012, by and among Response Genetics, Inc., a Delaware corporation (the “Company”), and (the “Investor”). Recitals A. The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions

RGDXQ / Response Genetics, Inc. / Northern Right Capital Management, L.P. - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment

AMENDMENT NO. 4 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* RESPONSE GENETICS, INC. (Name of issuer) Common Stock (Title of class of securities) 76123U105 (CUSIP number) Becker Drapkin Management, L.P. Attn: Steven R. Becker 300 Crescent Court, Suite 1111 Dallas, Texas 75201 (214)

RGDXQ / Response Genetics, Inc. / Danenberg Kathleen - KATHLEEN DANENBERG SC 13GA 10-7-2011 (RESPONSE GENETICS, INC) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No 2) Response Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 76123U105 (CUSIP Number) October 7, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule